Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

E
East, Lilly

Sarepta Therapeutics, Inc.
PII-138 - PHARMACOMETRICS-BASED APPROACH TO DEMONSTRATE CLINICAL EVIDENCE OF DELANDISTROGENE MOXEPARVOVEC BIOLOGICAL EFFICACY AND MECHANISM OF ACTION IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY.
Lilly East
Favorite
PWI-005 - PHARMACOMETRICS-BASED APPROACH TO DEMONSTRATE CLINICAL EVIDENCE OF DELANDISTROGENE MOXEPARVOVEC BIOLOGICAL EFFICACY AND MECHANISM OF ACTION IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY.
Lilly East
Favorite
Elashkar, Omar

Department of Pharmaceutics, College of Pharmacy, University of Florida
PII-009 - DECIPHERING TYPE 1 DIABETES BY INTEGRATING ARTIFICIAL INTELLIGENCE WITH PANCREATIC WHOLE SLIDE IMAGING
Omar Elashkar
Favorite
Eltanameli, Bassma

University of Florida College of Pharmacy
LB-032 - PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES
Bassma Eltanameli
Favorite
Emery, Maurice

Akamai Clin Pharm Consulting, Inc.
LB-033 - ROLE OF P-GLYCOPROTEIN IN THE INTESTINAL ABSORPTION OF MAVODELPAR IN HUMANS: SUPPORT FROM A PBPK MODEL.
Maurice Emery
Favorite
Evans, Martin

Walter Reed Army Institute of Research
PII-039 - PLERIXAFOR AS PATHOGEN AGNOSTIC PROPHYLAXIS OR ADVUVANT TREATMENT
Martin Evans
Favorite
Ezuruike, Udoamaka

Certara UK (Simcyp Division)
LB-003 - A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA).
Udoamaka Ezuruike
Favorite